Your browser doesn't support javascript.
loading
STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.
Curran, Emily; Chen, Xiufen; Corrales, Leticia; Kline, Douglas E; Dubensky, Thomas W; Duttagupta, Priyanka; Kortylewski, Marcin; Kline, Justin.
Afiliación
  • Curran E; Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
  • Chen X; Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
  • Corrales L; Department of Pathology, University of Chicago, Chicago, IL 60637, USA.
  • Kline DE; Department of Medicine, University of Chicago, Chicago, IL 60637, USA; Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.
  • Dubensky TW; Aduro Biotech, Inc., Berkeley, CA 94710, USA.
  • Duttagupta P; Department of Immuno-Oncology, Beckman Research Institute at City of Hope, Duarte, CA 91010, USA.
  • Kortylewski M; Department of Immuno-Oncology, Beckman Research Institute at City of Hope, Duarte, CA 91010, USA.
  • Kline J; Department of Medicine, University of Chicago, Chicago, IL 60637, USA; Committee on Immunology, University of Chicago, Chicago, IL 60637, USA. Electronic address: jkline@medicine.bsd.uchicago.edu.
Cell Rep ; 15(11): 2357-66, 2016 06 14.
Article en En | MEDLINE | ID: mdl-27264175
Type I interferon (IFN), essential for spontaneous T cell priming against solid tumors, is generated through recognition of tumor DNA by STING. Interestingly, we observe that type I IFN is not elicited in animals with disseminated acute myeloid leukemia (AML). Further, survival of leukemia-bearing animals is not diminished in the absence of type I IFN signaling, suggesting that STING may not be triggered by AML. However, the STING agonist, DMXAA, induces expression of IFN-ß and other inflammatory cytokines, promotes dendritic cell (DC) maturation, and results in the striking expansion of leukemia-specific T cells. Systemic DMXAA administration significantly extends survival in two AML models. The therapeutic effect of DMXAA is only partially dependent on host type I IFN signaling, suggesting that other cytokines are important. A synthetic cyclic dinucleotide that also activates human STING provided a similar anti-leukemic effect. These data demonstrate that STING is a promising immunotherapeutic target in AML.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Transducción de Señal / Inmunidad Innata / Proteínas de la Membrana Límite: Animals / Humans Idioma: En Revista: Cell Rep Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Transducción de Señal / Inmunidad Innata / Proteínas de la Membrana Límite: Animals / Humans Idioma: En Revista: Cell Rep Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos